Fri.Feb 14, 2025

article thumbnail

EU reshapes HTAs: is the industry ready for it?

Pharmaceutical Technology

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

article thumbnail

‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Bio Pharma Dive

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for biotech stocks.

Marketing 164
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DMD market expected to grow to $5.2bn in the 7MM by 2033

Pharmaceutical Technology

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, the UK, and Japan - is projected to experience significant growth, with sales increasing from $2.3bn in 2023 to $5.2bn by 2033, according to leading data and analytics company GlobalData.

Marketing 147
article thumbnail

EU approves CSL's once-monthly HAE drug Andembry

pharmaphorum

The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst

Drugs 71
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Galderma enters fierce European atopic dermatitis market with Nemluvio approval

Pharmaceutical Technology

Nemluvio, which was also approved for prurigo nodularis, becomes Galdermas first approved biologic in its dermatology arsenal.

article thumbnail

Apple study will look at the role tech can play in health

pharmaphorum

Apple has started a major new health study to see how devices like the iPhone, Apple Watch, and AirPods can be used to monitor and improve our health.

69

More Trending

article thumbnail

Taking the quantum leap: How life science real estate clusters accelerate innovation

pharmaphorum

Discover how life science real estate clusters drive innovation and collaboration, leading to groundbreaking advancements in the industry. Explore the impact of these clusters and how they propel progress in life sciences.

article thumbnail

Health Canada approves Novartis’ Fabhalta for PNH with haemolytic anaemia

Pharmaceutical Technology

Health Canada has approved Novartis Canadas Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with PNH.

147
147
article thumbnail

BMS study of Opdualag in adjuvant melanoma ends in failure

pharmaphorum

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study.

56
article thumbnail

Axplora Invests $52.5 Million into GLP-1 Manufacturing Facility

Pharmaceutical Commerce

The companys Mourenx plant in Southwest France aims to become an API network hub, with first supplies expected by next year.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Pharma digitalisation and transformation of HCP engagement with KAMs

pharmaphorum

Watch the video interview featuring Chris Moore, President Europe at Veeva, and Nicole Raleigh, Web Editor at pharmaphorum, as they discuss industry trends and insights.

52
article thumbnail

How HCPs and Patients Influence the CGT Approval Process

Pharmaceutical Commerce

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, describes why these pharma supply chain stakeholders are vital in understanding meaningful clinical outcomes.

52
article thumbnail

RFK Jr-led commission will assess 'threats' to children

pharmaphorum

New HHS Secretary RFK Fr has been given the task of investigating child health in the US, including whether some medicines may pose a threat.

article thumbnail

Pharma Pulse 2/14/25: RFK Jr. Confirmed as HHS Secretary, How Pharma Can Effectively Combat Misinformation & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

52
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

First self-amplifying mRNA vaccine reaches Europe

pharmaphorum

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU

article thumbnail

EC approves CSL’s Andembry to stop hereditary angioedema attacks

Pharmaceutical Technology

CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 years and above.

147
147
article thumbnail

Top 20 Publicly Traded Healthcare Companies by Market Cap in 2025

XTalks

Many people wonder how to gauge a companys influence in the healthcare sector. One way is to look at its market capitalization, which is the total value of its shares on the stock market. A larger market cap can signal stability, global reach and a strong capacity to address real-world challenges. In healthcare, these challenges often revolve around improving patient access, lowering costs and driving medical innovation.

article thumbnail

Study Reveals Key Predictors of Early Patent Challenges for FDA-Approved Drugs

Drug Patent Watch

The Hidden Risks of FDA-Approved Drugs: What You Need to Know As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug development and approval. But have you ever stopped to think about what happens after a drug receives FDA approval? While it's a major milestone, it's not the end of the road for many pharmaceuticals.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Compliance is Futile without Transparency: 340B, MDRP, MFP Overlap lead to Iceberg Ahead

Drug Channels

Todays guest post comes from Angie Franks, CEO at Kalderos Angie describes the compliance challenges that stakeholders face in managing the complex interactions of the 340B Drug Pricing Program, the Medicaid Drug Rebate Program, and IRAs Maximum Fair Price and inflation rebate provisions. She explains how clean, comprehensive claims datacan resolve these issues.